Seres Therapeutics (MCRB) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Seres Therapeutics (MCRB) over the last 6 years, with Q3 2025 value amounting to $0.94.
- Seres Therapeutics' EPS (Weighted Average and Diluted) fell 9191.75% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.29, marking a year-over-year increase of 96470.59%. This contributed to the annual value of $0.81 for FY2024, which is 15437.64% up from last year.
- As of Q3 2025, Seres Therapeutics' EPS (Weighted Average and Diluted) stood at $0.94, which was down 9191.75% from -$2.27 recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' EPS (Weighted Average and Diluted) peaked at $13.87 during Q4 2024, and registered a low of -$5.49 during Q1 2024.
- For the 5-year period, Seres Therapeutics' EPS (Weighted Average and Diluted) averaged around $0.81, with its median value being -$0.51 (2021).
- Examining YoY changes over the last 5 years, Seres Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 523703.7% in 2024 and a maximum decrease of 130555.56% in 2024.
- Quarter analysis of 5 years shows Seres Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.55 in 2021, then grew by 1.82% to -$0.54 in 2022, then skyrocketed by 50.0% to -$0.27 in 2023, then soared by 5237.04% to $13.87 in 2024, then tumbled by 93.22% to $0.94 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.94 for Q3 2025, versus -$2.27 for Q2 2025 and $3.75 for Q1 2025.